BURZYNSKI RESEARCH INSTITUTE INC (BZYR)

Current Report Filed: 2026-04-23

CFO departure: Patryk P. Goscianski resigned as CFO and Secretary effective April 17, 2026, with no stated disagreements regarding company operations, suggesting an amicable transition.
Consolidation of leadership: Dr. Stanislaw R. Burzynski (age 83), the controlling stockholder and President/Chairman, assumed the dual role of CFO and principal financial officer without additional compensation, which raises governance concerns regarding lack of independent financial oversight.
Potential governance risk: The appointment creates a significant concentration of power with one individual serving as President, Chairman, CEO, and CFO, reducing checks and balances typically expected in corporate governance structures.
Related party relationships: Dr. Burzynski maintains multiple material agreements with the company (New License Agreement, Amended and Restated Research Funding Agreement, and Royalty Agreement) that now require enhanced scrutiny given his expanded financial control.

Quarterly Report Filed: 2026-01-13

The company's retained earnings and additional paid-in capital have been steadily increasing over the past few years, indicating potential financial stability and growth.
The majority shareholder and president has entered into various licensing agreements and research and development arrangements, which could provide additional revenue streams and growth opportunities.
The company has received funding for clinical trials, research, and operational support from related parties, potentially helping to finance its ongoing operations and development efforts.

Important Information